Epithelial dysregulation in obese severe asthmatics with gastro-oesophageal reflux.

Competing Interests: Conflict of interest: J.M. Perotin has nothing to disclose. Conflict of interest: J.P.R. Schofield has nothing to disclose. Conflict of interest: S.J. Wilson has nothing to disclose. Conflict of interest: J. Ward has nothing to disclose. Conflict of interest: J. Brandsma has nothing to disclose. Conflict of interest: F. Strazzeri has nothing to disclose. Conflict of interest: A. Bansal has nothing to disclose. Conflict of interest: X. Yang has nothing to disclose. Conflict of interest: A. Rowe is a full-time employee and shareholder of Janssen Pharmaceutical Companies of Johnson and Johnson. Conflict of interest: J. Corfield has nothing to disclose. Conflict of interest: R. Lutter has nothing to disclose. Conflict of interest: D.E. Shaw reports fees for lectures at company sponsored symposia and support to attend an international conference from AstraZeneca, fees for lectures at company sponsored symposia and investigator-initiated research funding from Boehringer Ingelheim, fees for lectures at company sponsored symposia from Novartis and Teva, a fee for presentation from Circassia, and a grant for an investigator led study from GSK, outside the submitted work. Conflict of interest: P.S. Bakke reports personal fees from GSK, AZ, Novartis andTeva, outside the submitted work. Conflict of interest: M. Caruso has no conflict of interest to disclose. Conflict of interest: B. Dahlén has nothing to disclose. Conflict of interest: S.J. Fowler reports personal fees and non-financial support from AstraZeneca, grants and personal fees from Boehringer Ingelheim, and personal fees from Novartis and Teva, outside the submitted work. Conflict of interest: I. Horváth reports personal fees from Astra Zeneca, Boehringer Ingelheim, Novartis, CSL, Chiesi, Roche, GSK, Berlin-Chemie and Sandoz, outside the submitted work. Conflict of interest: P. Howarth reports personal fees from GSK, outside the submitted work. Conflict of interest: N. Krug has nothing to disclose. Conflict of interest: P. Montuschi has nothing to disclose. Conflict of interest: M. Sanak has nothing to disclose. Conflict of interest: T. Sandström reports Fees for lectures and course arrangement from Boehringer Ingelheim, outside the submitted work. Conflict of interest: K. Sun has nothing to disclose. Conflict of interest: I. Pandis has nothing to disclose. Conflict of interest: C. Auffray reports grants from Innovative Medicine Initiative, during the conduct of the study. Conflict of interest: B. De Meulder reports grants from Innovative Medicine Initiative, during the conduct of the study. Conflict of interest: D. Lefaudeux reports grants from Innovative Medicine Initiative, grants from Innovative Medicine Initiative, during the conduct of the study. Conflict of interest: J.H. Riley reports that he has shares in and is employed by GSK. Conflict of interest: A.R. Sousa has nothing to disclose. Conflict of interest: S-E. Dahlén has nothing to disclose. Conflict of interest: I.M. Adcock reports grants from EU-IMI, during the conduct of the study. Conflict of interest: K.F. Chung has received honoraria for participating in Advisory Board meetings of GSK, AZ, BI, Teva, Novartis and Merck regarding treatments for asthma and chronic obstructive pulmonary disease, and has also been renumerated for speaking engagements. Conflict of interest: P.J. Sterk reports grants from Innovative Medicines Initiative, during the conduct of the study. Conflict of interest: P.J. Skipp has nothing to disclose. Conflict of interest: J.E. Collins reports a patent application for use of a genetically modified Drosophila line carrying one or more mammalian genes associated with a chronic respiratory disease and uses to screen the impact of such genes. Conflict of interest: D.E. Davies has nothing to disclose. Conflict of interest: R. Djukanović reports receiving fees for lectures at symposia organised by Novartis, AstraZeneca and TEVA, consultation for TEVA and Novartis as member of advisory boards, and participation in a scientific discussion about asthma organised by GlaxoSmithKline. He is a co-founder and current consultant, and has shares in Synairgen, a University of Southampton spin out company.